Crucell to raise EUR 80 million, acquire SBL

Crucell (Euronext:CRXL; CRXL) said it plans to raise EUR 80 million ($102.6 million) through the sale of new ordinary shares. CRXL plans to use a portion of the funds to acquire vaccine company SBL (Stockholm, Sweden) for EUR 39.4 million ($50.5 million) in cash. The deal gives CRXL Dukoral, an oral vaccine to prevent cholera and travelers' diarrhea that had about EUR 14 million ($16.6 million) in 2005 sales. CRXL also said the deal strengthens its sales organization in Scandinavia. SBL had nine-month revenues of EUR 17.6 million ($22.3 million). CRXL's marketed travel vaccines include Epaxal for hepatitis A and Vivotif for typhoid. ...